DeLLphi Clinical Trials are available to patients with Small-Cell Lung Cancer (SCLC)
Amgen Oncology is testing the investigational drug tarlatamab to see how safe and effective it is at treating patients who have small-cell lung cancer (SCLC).
DeLLphi-305 (Extensive-Stage SCLC)
DeLLphi-306 (Limited-Stage SCLC)
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
